Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: george willse who wrote (1816)	6/25/1998 6:51:00 PM
From: Hyrulean King	Read Replies (1) \| Respond to of 5402

SGNC is a fully reporting company. You made good points there, the $300 figure is high for 3rd world countries, but the benefit is the long 3 1/2 year shelf life for their money. Chief

To: george willse who wrote (1816)	6/25/1998 6:53:00 PM
From: Prospector	Respond to of 5402

Welcome George boy it didn't take too long fer you to see which side of the bread was buttered... Prospector( allot of smart folks comin round )

To: george willse who wrote (1816)	6/25/1998 6:57:00 PM
From: R>G>	Read Replies (1) \| Respond to of 5402

Milestones/Time Lines (From Sanguine's business plan) 1-6 months. Preform preliminary gross animal tests 6-12 months. Conduct animal safety and efficacy trials. Make strategic Alliance with large pharmaceutical firm. 12-30 months. A. Simultaneously prepare IND applications for European and United States FDA approvals, revive clinical trials with Italian Red Cross and Health Ministry,Erasmun University, Rotterdam, et al. B. Conduct trials for cardioplegia, cancer and cardiology in United States, but transfusion elsewhere. 30-33 months Submit license applications to Italian, Dutch, et al. Begin production as Subcontractors. 33-36 months. A. Submit United States New Drug Application (NDA). B. Begin sales in Italy, Holland and other countries which accept their drug approvals. 36 A. Begin United States and Canada sales for cancer and PTCA. Continue trials on other applications, transplant organ preservation, Co poisoning, sickle cell anemia, stroke and heart attack, et al. Welcome to the board